Assertio

Assertio is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of pain and other central nervous system disorders. Founded in 1995, the company has built itself by developing and incorporating promising technologies into differentiated therapeutic products, gaining clinical approval for these products, and establishing a strong market position. The company currently markets four FDA-approved products: Gralise® (gabapentin) tablets for the treatment of postherpetic neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults aged 18 years or older, Zipsor® (diclofenac potassium) liquid-filled capsules for the relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the treatment of breakthrough pain in cancer patients.On August 14, 2018, the company officially changed its name from Depomed, Inc. to Assertio Therapeutics, Inc.